Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma
This is an open label, single arm, phase I/II for patients with r/r Non-Hodgkin's Lymphoma

. The purpose is to evaluate the safety and efficacy of the combination with Azacytidine, Bendamustine and Piamprizumab
Non-hodgkin Lymphoma,B Cell
DRUG: Azacytidine, Bendamustine and Piamprizumab
Safety: treatment-related adverse events (AEs), Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0. AEs were considered to be treatment-related if they had started or worsened within the interval from first study drug administration until the follow-up visit., 6 month
Objective Response Rate, The ORR is defined as the proportion of patients with a best overall disease response, including complete response (CR) and partial response (PR)., 6 month|Complete Response Rate, CR rate assess by investigators per the 2014 Lugano classification rate of subjects achieved complete response in all evaluable subjects, 6 month
This is an open label, single arm, phase I/II for patients with r/r Non-Hodgkin's Lymphoma

. The purpose is to evaluate the safety and efficacy of the combination with Azacytidine, Bendamustine and Piamprizumab